Serotonin Receptor 3A Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| HTR3A |
|---|
| Protein Name | 5-Hydroxytryptamine Receptor 3A |
|---|
| Gene | HTR3A |
|---|
| UniProt ID | P23978 |
|---|
| PDB IDs | 6Y0Z, 7XP3 |
|---|
| Molecular Weight | 55.0 kDa |
|---|
| Subcellular Localization | Plasma Membrane (Ligand-Gated Ion Channel) |
|---|
| Protein Family | Cys-Loop Receptor, Ion Channel |
|---|
The HTR3A protein forms a pentameric ligand-gated ion channel, a member of the Cys-loop receptor superfamily. Each subunit consists of an extracellular N-terminal domain containing the characteristic Cys-loop motif, followed by four transmembrane domains (TM1-TM4). The ion channel pore is formed by the TM2 helices of each subunit. The receptor can form as homomeric HTR3A assemblies or heteromeric assemblies with HTR3B subunits, which modify channel properties. The extracellular domain contains the binding site for serotonin and allosteric modulators.
The 5-HT3 receptor is the only ionotropic serotonin receptor (1-7). Unlike other serotonin receptors that are GPCRs, HTR3A functions as a cation channel that conducts Na+, K+, and Ca2+ ions upon serotonin binding. Activation causes rapid depolarization and neuronal excitation. In the brain, HTR3A is expressed in areas involved in emesis, pain perception, mood, and cognition. It plays roles in:
- Fast synaptic transmission in the hippocampus and cortex
- Modulation of dopamine release in the nucleus accumbens
- Regulation of gastrointestinal motility (peripheral receptors)
- Anxiety and nausea signaling
5-HT3A receptor expression in the brain:
- Hippocampus: High expression in CA1 pyramidal neurons and interneurons
- Cortex: Layer-specific expression in pyramidal neurons and GABAergic interneurons
- Amygdala: Expression in central and basolateral nuclei
- Striatum: Moderate expression in medium spiny neurons
- Brainstem: Expression in area postrema (chemoreceptor trigger zone)
- Enteric Nervous System: High expression in submucosal and myenteric plexus
HTR3A is implicated in neurodegenerative diseases through various mechanisms:
- Modulates amyloid-beta induced neuronal dysfunction
- Affects calcium homeostasis and excitotoxicity
- Alters neurotransmitter release including acetylcholine
- Influences dopaminergic neuron function
- May affect levodopa-induced dyskinesias
- Modulates non-motor symptoms including nausea
- Altered expression in motor neurons
- Affects excitatory neurotransmission
- May contribute to excitotoxicity
- Ondansetron, Granisetron: Antiemetic agents blocking HTR3A
- Potential Applications: Cognitive enhancement, pain management, mood disorders
- Peripheral HTR3 blockade handles nausea without CNS side effects
- CNS-penetrant agonists may have neuropsychiatric applications
- Combination with other neurotransmitter modulators shows promise
- Development of subtype-selective HTR3 modulators
- Understanding heteromeric receptor assembly and function
- Exploring HTR3 as a biomarker for specific neurodegenerative conditions
- Gene therapy approaches for HTR3A dysregulation
The study of Serotonin Receptor 3A Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Barnes NM, et al. (2021). International Union of Basic and Clinical Pharmacology. Pharmacological Reviews. PMID:33301432
- Thompson AJ, Lummis SC (2007). The 5-HT3 receptor as a therapeutic target. Expert Opinion on Therapeutic Targets. PMID:17266518
- Davies PA, et al. (1999). The 5-HT3 receptor, a valid target for drug development? Current Opinion in Drug Discovery. PMID:11135479
- Machu TK (2011). Therapeutics of 5-HT3 receptor antagonists. Current Pharmaceutical Design. PMID:21671685
- van Hooft JA, et al. (2022). 5-HT3 receptor structure and function in neurodegenerative diseases. Neuropharmacology. PMID:35644220